Meryx

About:

Meryx is a biotechnology company that develops orally bio-available cancer drugs targeting receptor tyrosine kinases.

Description:

Meryx is a biotechnology company that develops orally bio-available cancer drugs targeting receptor tyrosine kinases. It focuses on developing drugs that inhibit tumor growth and initiate anti-tumor immunity in a range of cancers such as leukemia, lung cancer, and melanoma. It offers potent inhibitors of MerTK, such as MRX-2843, a clinical drug candidate; and MRX-6313, a backup candidate that inhibit growth and initiate anti-tumor immunity in a range of hematologic and solid malignancies. Meryx was founded in 2013 and is based in Chapel Hill, North Carolina.

Total Funding Amount:

$5.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Chapel Hill, North Carolina, United States

Founded Date:

2013-01-01

Founders:

Douglas Graham, H. Shelton Earp, Stephen Frye

Number of Employees:

1-10

Last Funding Date:

2015-06-23

IPO Status:

Private

Industries: